2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Forbes, J. M. Articles by Thomas, M. C. Search for Related Content PubMed PubMed Citation Articles by Forbes, J. M. Articles by Thomas, M. C.

Role of Advanced Glycation End Products in Diabetic Nephropathy

Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.

Correspondence to Dr. Merlin Thomas, Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, P.O. Box 6492, Melbourne, VIC 8008, Australia; Phone: +61-3-85321280; Fax: +61-3-85321480;

ABSTRACT. Nonenzymatic reactions between sugars and the free amino groups on proteins, lipids, and nucleic acids result in molecular dysfunction through the formation of advanced glycation end products (AGE). AGE have a wide range of chemical, cellular, and tissue effects through changes in charge, solubility, and conformation that characterize molecular senescence. AGE also interact with specific receptors and binding proteins to influence the expression of growth factors and cytokines, including TGF-1 and CTGF, thereby regulating the growth and proliferation of the various renal cell types. It seems that many of the pathogenic changes that occur in diabetic nephropathy may be induced by AGE. Drugs that either inhibit the formation of AGE or break AGE-induced cross-links have been shown to be renoprotective in experimental models of diabetic nephropathy. AGE are able to stimulate directly the production of extracellular matrix and inhibit its degradation. AGE modification of matrix proteins is also able to disrupt matrix–matrix and matrix–cell interactions, contributing to their profibrotic action. In addition, AGE significantly interact with the renin-angiotensin system. Recent studies have suggested that angiotensin-converting enzyme inhibitors are able to reduce the accumulation of AGE in diabetes, possibly via the inhibition of oxidative stress. This interaction may be a particularly important pathway for the development of AGE-induced damage, as it also can be attenuated by antioxidant therapy. In addition to being a consequence of oxidative stress, it is now clear that AGE can promote the generation of reactive oxygen species. It is likely that therapies that inhibit the formation of AGE will form an important part of future therapy in patients with diabetes, acting synergistically with conventional approaches to prevent diabetic renal injury. E-mail: merlin.thomas@baker.edu.au

This article has been cited by other articles:

				K. Yoh, A. Hirayama, K. Ishizaki, A. Yamada, M. Takeuchi, S.-i. Yamagishi, N. Morito, T. Nakano, M. Ojima, H. Shimohata, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice Genes Cells, November 1, 2008; 13(11): 1159 - 1170. [Abstract] [Full Text] [PDF]

				W. C. Burns, S. M. Twigg, J. M. Forbes, J. Pete, C. Tikellis, V. Thallas-Bonke, M. C. Thomas, M. E. Cooper, and P. Kantharidis Connective Tissue Growth Factor Plays an Important Role in Advanced Glycation End Product-Induced Tubular Epithelial-to-Mesenchymal Transition: Implications for Diabetic Renal Disease J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2484 - 2494. [Abstract] [Full Text] [PDF]

				S. Kooptiwut, M. Kebede, S. Zraika, S. Visinoni, K. Aston-Mourney, J. Favaloro, C. Tikellis, M. C Thomas, J. M Forbes, M. E Cooper, et al. High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction J. Mol. Endocrinol., August 1, 2005; 35(1): 39 - 48. [Abstract] [Full Text] [PDF]

				K. Kankova, A. Stejskalova, M. Hertlova, and V. Znojil Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1093 - 1102. [Abstract] [Full Text] [PDF]

				H. J. Han, Y. J. Lee, S. H. Park, J. H. Lee, and M. Taub High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells Am J Physiol Renal Physiol, May 1, 2005; 288(5): F988 - F996. [Abstract] [Full Text] [PDF]

				M. C. Thomas, C. Tikellis, P. Kantharidis, W. C. Burns, M. E. Cooper, and J. M. Forbes The Role of Advanced Glycation in Reduced Organic Cation Transport Associated with Experimental Diabetes J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 456 - 466. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673